


# HHV8 DNA QUANTITATION (QT)

**Real -Time PCR  
for the HHV8 genome  
Quantification**

-for "in vitro" diagnostic use only-



REF. HHV8DNAQT.CE  
25/50/100/150 Tests

## HHV8 DNA

### A. INTENDED USE

The **HHV8 DNA Quantitation (QT)** Real-Time PCR kit coded **HHV8DNAQT.CE** is intended for the quantitative detection of Human herpesvirus 8 DNA in human plasma/blood with a simultaneous control of the extraction/amplification reaction through an **Internal Control (IC)**.

The kit has been adapted for the use on the Real-Time Thermocyclers and ABI 7500 Sequence Detection System® (Software SDS version 1.3.1, Applied Biosystems™\*) or MiniOpticon® (Software CFX manager version 1.6, Biorad™\*\*) or MX3000P (Software MxPro version 4.01, Stratagene™\*\*\*).

\* Applied Biosystems is a registered trademark and ABI PRISM® is a trademark of Applied Biosystems Corporation or its subsidiaries in the US and/or certain other countries.

\*\* Biorad is a registered trademark.

\*\*\*Stratagene is a registered trademark.

### B. INTRODUCTION

HHV-8 is a member of the Gammaherpesvirinae subfamily. The prevalence of HHV-8 infection varies widely, from approximately 1–3% of the general population in North America to more than 70% in several regions of Africa where HHV-8 is endemic. HHV-8, also known as Kaposi's sarcoma associated herpesvirus, has been associated with Kaposi's disease, multicentric Castlemann's disease, primary effusion lymphoma and other plasmablastic lymphoma classified as diffuse large B-cell lymphoma.

The complete HHV-8 genome sequence shows that it has sequence similarities to other gammaherpesviruses including, herpesvirus saimiri (HVS), murine gammaherpesvirus 68 (MHV68) and Epstein-Barr Virus (HHV-4). The ~165 kb genome contains over 80 open reading frames arranged in a long unique region flanked by multiple 801bp terminal repeat units of high G+C content. The long unique region contains blocks of conserved genes found in most herpesviruses, interspersed with blocks of non-homologous genes that are specific for HHV-8 and related viruses.

An increasing number of antiviral agents are available for treatment and prevention of these infection. In addition, interferons and immunoglobulin preparations have been utilized. Real-time PCR using peripheral blood is an effective diagnostic tool for the detection and quantitation of HHV-8 active replication particularly in immunocompromised patients.

The amount of HHV8 DNA detected in the biological samples correlates with clinical Kaposi's disease staging. Therefore, it is necessary to follow up patients with specific HHV8 disease using quantitative assay for detection of HHV8 DNA, in order to better observe the evolution of the disease and the efficiency of treatment administered.

### C. PRINCIPLE OF THE TEST

The CMVDNAQT.CE Kit is based on a Real Time chemistry which uses specific Primers and Probes,

**HHV8 DNA**, recovered from the biological sample under investigation through an extraction step, and amplified using Real Time amplification system. The amplified product, is detected and quantified, against the standard curve using a fluorescent reporter dye probe specific for a HHV8 unique genomic sequence.

Heterologous Internal Control (IC) serves as an extraction/amplification control for each individually processed specimen aiming to the identification of reaction inhibitors.

A standard curve is supplied allowing the determination of the viral load.

### D. COMPONENTS

The standard format of the product code HHV8DNAQT.CE contains reagents for 50 tests.

Component	Contents	HHV8DNAQT.CE 50 Reactions
<b>A</b> CODED: ALL/MM COLOR CODE: LIGHT BLUE	Master mix	N°2 vials / 0.4ml
<b>B</b> CODED: HHV8/CB COLOR CODE: YELLOW	Lyophilised Primers/Probes	N°2 vials (Dissolve with the volume of ALL/C indicated on the vial label)
<b>C</b> CODED: ALL/C COLOR CODE: GRAY	MG Water	N°2 vials /1.5 ml
<b>NTC</b> CODED: ALL/NTC COLOR CODE: WHITE	Negative Control	N°1 vials /1.5 ml
<b>STD</b> Quantitation Standard (3.5x10 <sup>5</sup> copies/μl) CODED: HHV8/STD COLOR CODE: RED	Lyophilised Quantitative Standard	N°2 vials (Dissolve with the volume of ALL/C indicated on the vial label)
<b>I.C.</b> Internal Control CODED: ALL/IC COLOR CODE: GREEN	Lyophilised Internal Control	N°2 vials (Dissolve with the volume of ALL/C indicated on the vial label)
Package Insert	Instruction for Use	1

**Important note:** Upon request, Dia.Pro can supply reagents for 25, 100, 150 tests, as reported below :

1. Component A	n°1 vial/0.4 ml	n°4 vials/0.4 ml	n°6vials/0.4 ml
2. Component B	n°1 vial	n°4 vials	n°6 vials
3. Component C	n°1 vial/1.5 ml	n°4 vial/1.5 ml	n°5 vial/1.5 ml
4. NTC	n°1 vial/1.5 ml	n°1 vial/1.5 ml	n°1 vial/1.5 ml
6. IC	n°1 vial	n°4 vials	n°6 vials
7. STD	n°1 vial	n°4 vials	n°6 vials
8. Pack. insert	n°1	n°1	n°1
<b>Number of tests</b>	<b>25</b>	<b>100</b>	<b>150</b>
<b>Code</b>	<b>HHV8DNAQT.CE.25</b>	<b>HHV8DNAQT.CE.100</b>	<b>HHV8DNAQT.CE.150</b>

### E. STORAGE AND STABILITY

The kit HHV8DNAQT.CE must be stored at +4...8 °C . On ce dissolved store at -20°C **Component B**(coded HHV8/CB), **Component IC** (coded ALL/IC) and **component STD** (coded HHV8/STD) and use them within 2 weeks. If the components are to be used only intermittently, they should be frozen in aliquots, repeated thawing and freezing should be avoided, Only one defreezing is allowed.

Doc.:	INS HHV8DNAQT.CE	Page	3 of 9	Rev.: 4	Date: 11/2011
-------	------------------	------	--------	---------	---------------

## F. MATERIALS REQUIRED BUT NOT PROVIDED

1. Calibrated Micropipettes ( 0.5 µl < volume <1000 µl )
2. DNA extraction kit
3. MG EtOH
4. Thermal Block
5. Microcentrifuge
6. Tube racks
7. Sterile filtered tips with aerosol barrier
8. Nuclease-Free Microtubes
9. 0,2 ml Microtubes or Pcr Microplates recommended from the Real-Time PCR instruments manufacturers
10. Disposable gloves, powder-free
11. Real-Time PCR Thermalcycler (\*)
12. Absorbent paper tissues.
13. Vortex or similar mixing tools.

(\*) **Attention:** A valid calibration of the pure dyes (Pure Spectra Component File) and of the background (Background Component File) must be done routinely.

## G. WARNINGS AND PRECAUTIONS

1. The kit has to be used by skilled and properly trained technical personnel only, under the supervision of a medical doctor responsible for the laboratory.
2. The technical personnel must be deeply trained in the use of Real-Time thermalcyclers, in the manipulation of Molecular Biology reagents and in the Real-Time PCR amplification protocols.
3. The kit has to be used in a laboratory certified and qualified by the national authority in that field (Ministry of Health or similar entity) to carry out this type of analysis.
4. All the personnel involved in performing the assay have to wear protective laboratory clothes, powder-free gloves and glasses. The use of any sharp (needles) or cutting (blades) devices should be avoided. All the personnel involved should be trained in biosafety procedures, as recommended by the Center for Disease Control, Atlanta, U.S. and reported in the National Institute of Health's publication: "Biosafety in Microbiological and Biomedical Laboratories", ed. 1984.
5. All the personnel involved in sample handling should be vaccinated for HBV and HAV, for which vaccines are available, safe and effective.
6. The laboratory environment should be controlled so as to avoid contaminants such as dust or air-borne microbial agents,
7. Components A and B are light sensitive. Protect them from strong light exposition.
8. Avoid vibration of the bench surface where the test is undertaken.
9. Upon receipt, store the kit at 2.8°C into a temperature controlled refrigerator or cold room.
10. Do not interchange components between different lots of the kits. It is recommended that components between two kits of the same lot should not be interchanged.
11. Check that the reagents are clear and do not contain visible heavy particles or aggregates. If not, advise the laboratory supervisor to initiate the necessary procedures for kit replacement.
12. Avoid cross-contamination between samples by using disposable tips and changing them after each sample.
13. Avoid cross-contamination between kit reagents by using disposable tips and changing them between the use of each one.
14. Do not use the kit after the expiration date stated on the external container label.
15. Treat all specimens as potentially infective. All human serum/blood/plasma specimens should be handled at Biosafety Level 2, as recommended by the Center for Disease Control, Atlanta, U.S. in compliance with what reported in the Institutes of Health's publication: "Biosafety in Microbiological and Biomedical Laboratories", ed. 1984.
16. Store and extract specimens separately from the other reagents and use a separate room for their handling

17. Dissolve the lyophilised reagents with the correct amount, (stated in the labels) of Component C (Coded: ALL/C) supplied in the kit.

18. Carry on all the working operations as quickly as possible maintaining the components on ice or in a cooling block.

19. The laboratory Workflow must proceed in an unidirectional way, beginning in the Extraction Area and moving to the Amplification and Data Analysis Areas. Do not return samples, equipment and reagents to the area where previous steps have been performed.

20. The use of disposable plastic-ware is recommended in the preparation of the liquid components or in transferring components into automated workstations, in order to avoid cross contamination.

21. Waste produced during the use of the kit has to be discarded in compliance with national directives and laws concerning laboratory waste of chemical and biological substances. In particular, liquid waste generated from sample extraction procedures, has to be treated as potentially infective material and inactivated before waste. Do not put in contact the extraction waste with bleach.

22. Accidental spills from samples and operations have to be adsorbed with paper tissues soaked with household bleach and then with water. Tissues should then be discarded in proper containers designated for laboratory/hospital waste.

23. Other waste materials generated (example: tips used for samples) should be handled as potentially infective and disposed according to national directives and laws concerning laboratory wastes.

## H. SPECIMEN: PREPARATION AND RECOMMENDATIONS

1. Blood is drawn aseptically by venepuncture and plasma is prepared using standard techniques of preparation of samples for clinical laboratory analysis.

2. No influence has been observed in the preparation of the sample with citrate, EDTA.

Attention: Heparin ( $\geq 10$  IU/ml) affects the PCR reactions.

Samples, which has been collected in tubes containing heparin as an anticoagulant should not be used. Also, samples of heparinised patients must not be used.

3. Avoid any addition of preservatives to samples.

4. Samples have to be clearly identified with codes or names in order to avoid misinterpretation of results.

5. Haemolysed (red) and visibly hyperlipemic ("milky") samples have to be discarded as they could generate false results. Samples containing residues of fibrin or heavy particles or microbial filaments and bodies should be discarded as they could give rise to false results.

6. Plasma, if not used immediately, must be aliquoted and stored at -20°C.-80°C after collection. Samples can be stored frozen at -80°C for several months. Any frozen samples should not be frozen/thawed more than once as this may affect the test result.

7. The plasma samples for DNA extraction must be collected according to the common laboratory procedures, transported and stored at +2 / +8 °C for a maximum period of 4 hours. The plasma samples can be stored frozen at -20°C for a maximum period of 30 days or at -70 °C for longer periods.

8. We recommend you, for optimal storage of samples, to split them in several aliquots (minimum volume 300 µl) and store them frozen at -20°C for a maximum period of 30 day or -70°C for longer periods. Avoid repeated freezing / thawing cycles.

9. When using frozen samples, thaw the samples just immediately before the extraction in order to avoid possible cases of nucleic acid degradation.

10. The whole peripheral blood samples for DNA extraction must be collected in EDTA according to laboratory advices, transported and stored at +2 / +8 °C for a maximum period of 3 days. Do not freeze the whole peripheral blood samples to avoid cell lysis and viral titre loss

## I. PREPARATION OF COMPONENTS AND WARNINGS

### Master Mix:

Component A. Ready to use. Mix well on vortex before use and centrifuge briefly to collect the whole volume.

**WARNING: Component A is light sensitive. Protect it from strong light exposition.**

### Primers/Probes:

#### Component B.

- Centrifuge the vial at 11000 rpm for 1 min.
- Open carefully the vial cap avoiding powder dispersion.
- Dissolve homogenously the Lyophilized Component B with the volume of water (Component C) indicated on the vial label.
- Keep it dissolve on the benchtop for at least 10 min at room temperature ( 15°C <RT< 25°C)
- Briefly vortex

**WARNING: Component B is light sensitive. Protect it from strong light exposition.**

### MG Water :

Component C. Ready to use.

### Negative Control :

NTC. Ready to use.

### Standard Curve:

#### STD.

- Centrifuge the vial at 11000 rpm for 1 min.
- Open carefully the vial cap avoiding powder dispersion.
- Dissolve homogenously the Lyophilized STD with the volume of Component C (Code: ALL/C) indicated on the vial label.
- Keep it dissolve on the benchtop for at least 10 min at room temperature ( 15°C <RT< 25°C)
- Briefly vortex
- Prepare the Nucleases-Free vials for the preparation of the Standard Curve
- Set up an STD 1:10 serial dilution in Component C (Code: ALL/C) to obtain the standard curve points as described in the table below:

Standard curve preparation		
STD	Calibrator	Add the Volume of Component C (Code: ALL/C) as written on the vial label
	<b>350000 copies/ µl</b>	
STD 1	<b>35000 copies/ µl</b>	10 µl (STD) + 90 µl Component C (Code: ALL/C)
STD 2	<b>3500 copies/ µl</b>	10 µl (STD 1) + 90 µl Component C (Code: ALL/C)
STD 3	<b>350 copies/ µl</b>	10 µl (STD 2) + 90 µl Component C (Code: ALL/C)
STD 4	<b>35 copies/ µl</b>	10 µl (STD 3) + 90 µl Component C (Code: ALL/C)

### Internal Control:

#### I.C.

- Centrifuge the vial at 11000 rpm for 1 min.
- Open carefully the vial cap avoiding the powder dispersion.
- Dissolve homogenously the Lyophilized I.C. with the volume of Component C (Code: ALL/C) indicated on the vial label.
- Keep it dissolve on the benchtop for at least 10 min at room temperature ( 15°C <RT< 25°C)
- Briefly vortex

## L. INSTRUMENTS AND TOOLS USED IN COMBINATION WITH THE KIT

1. **Micropipettes** have to be calibrated and must be submitted to regular decontamination (household alcohol, 10% solution of bleach, hospital grade disinfectants) of those parts that could accidentally come in contact with the sample. They should also be regularly maintained in order to show a precision of 1% and a trueness of +/-5%.
2. **Extraction Device:** The HHV8DNAQT.CE Kit is intended for the use in combination only with QIAamp DNA Minikit Code:51306 (QIAGEN), Nucleospin Blood kit Code: 740951(MN) and NA Body Fluid Kit Code: D-2021 (Chemagen distributed by Dia.Pro).. The end users must strictly follow the Instruction for use supplied by the manufacturers.
3. **Real-Time Thermocyclers.** The HHV8DNAQT.CE Kit is intended for the use in combination only with the Real Time Thermal cyclers ABI 7500, software SDS version 1.3.1 (Applied Biosystems), and MX3000P, software MxPro version 4.01 (Stratagene) and MiniOpticon, software CFX manager version 1.6 (Biorad). The end users must strictly follow the Instruments Instruction for use supplied by the manufacturers.

## M. PRE ASSAY CONTROLS AND OPERATIONS

1. Check the expiration date of the kit printed on the external label of the kit box. Do not use if expired.
2. Check that the liquid components are not contaminated by naked-eye visible particles or aggregates. Check that on the bottom of the Lyophilized components vials is present a well formed aggregate. Check that no breakage occurred in transportation and no spillage of liquid is present inside the box.
3. Dissolve the Lyophilized Components with the appropriate amount of Component C (Molecular Grade water) as described in the proper section (I).
4. Turn the Thermalcyclers on, check settings and be sure to use the right assay protocol.
5. Follow strickly the Instruments Manual supplied by the manufacturers for the correct setting of the Real-Time Thermalcyclers.
6. Check that the micropipettes are set to the required volume.
7. Check that all the other equipment is available and ready to use.
8. In case of problems, do not proceed further with the test and advise the supervisor.

## N. ASSAY PROCEDURE

The assay has to be carried out according to what reported below.

### N.1 DNA extraction

The extraction step of the HHV8 genomic DNA has to be carried out exclusively in combination with the following kits:

### Manual Extraction tools

Material	Description	Kit code	manufacturer
Plasma/Blood	Nucleospin Blood	740951	MN™
Plasma/Blood	QIAamp DNA mini kit®	51306	Qiagen™

### Automatic Extraction tool in combination with DIA.FASTEX Instrument

Material	Description	Kit code	Manufacturer
Plasma/Blood	NA Body Fluid Kit	D-2021	Chemagen distributed by Dia.Pro

The DNA isolation must be carried out only according to the Instruction Manual supplied by the Manufacturer (QIAGEN™, MN™, Chemagen).

**Important Note :** The following volumes have to be strictly used in the extraction procedures :

Description	Sample volume ul	Elution volume ul
Nucleospin Blood	200	100
QIAamp DNA mini kit®	200	100
NA Body Fluid Kit	200	200

The DNA extracted from the samples, not used in the run , has to be stored frozen (-20°C.....-80°C).

**Important note:** The IC of the HHV8DNAQT.CE Kit can be used in the isolation procedure as extraction control. The Internal Control Ct value for the negative samples is used to evaluate if the DNA extraction procedure has been performed correctly (see section Q).

#### For this application

- Nucleospin Blood and QIAamp DNA mini kit : **add 5 µl of I.C. to the lysis buffer and sample mixture and proceed following the instruction manual supplied by the manufacturer of the Extraction Kit.**
- NA Body Fluid Kit : **add 10 µl of I.C. to the sample (blood protocol) or to the lysis buffer and sample mixture (plasma protocol) and proceed following the instruction manual supplied by the manufacturer of the Extraction Kit.**

### N.2 Setting up of the reaction

HHV8DNAQT.CE kit is intended to be used exclusively in combination with ABI 7500, software SDS version 1.3.1 (Applied Biosystems), and MX3000P, software MxPro version 4.01 (Stratagene) and MiniOpticon ,software CFX manager version 1.6 (Biorad).

#### N.2.1 Preparing the PCR

**Important:** An example of dispensation scheme is reported in Section O. Please, refer to it before starting the operations described here below.

- Prepare the components as described in Section I;

- Prepare the required number of reaction tubes or a 96-well reaction plate for the samples under evaluation and for the Standard curve (prepared as described in Section I).

**Important note:** Use only optical tubes or microplates suggested by the Real-Time thermocyclers manufacturers.

- Consider that the samples, if possible, should be tested in duplicate;
- Include at least 1 tube for the NTC (negative control)
- Prepare the **Amplification Mix** for **Samples, NTC and standard curve** as table below:

#### Preparation of the Amplification Mix (IC as Amplification Control)

Number of Reactions	x1	x12	
<b>A</b>	Master mix	12,5 µl	150 µl
<b>B</b>	Primers/probes	2 µl	24 µl
<b>I.C.</b>	Internal Control	0,5 µl	6 µl
<b>Tot vol.</b>		<b>15 µl</b>	<b>180 µl</b>

**Important note:** If the Internal Control was added in the DNA isolation procedure, prepare the **Amplification Mix** for **Samples, NTC and standard curve** as table below:

#### Preparation of the Amplification Mix (IC as Extraction/Amplification control)

Number of Reactions	x1	x12	
<b>A</b>	Master mix	12,5 µl	150 µl
<b>B</b>	Primers/probes	2 µl	24 µl
<b>C</b>	MG Water	0,5 µl	6 µl
<b>Tot vol.</b>		<b>15 µl</b>	<b>180 µl</b>

### N.2.2 Amplification procedure

- Dispense 15 ul of the amplification mix in each reaction tube or microplate well
- Add 10 ul of the **Samples, NTC and standard curve** to the reaction tubes.
- Close firmly the reaction tubes
- Centrifuge briefly the reaction tubes at 2000 rpm
- Don't leave the reaction tubes at room temperature (RT) for more than 30 minute and at light exposure (cover the tubes).
- Load the tubes in the Real-Time Thermacycler Thermoblock Holder.
- After the setting operations described in the Sections N3 (Instrument Programming) start the Thermacycler run.

**Important note:** The Components Lyophilized after dissolution in Component C (MG water) are stable no more than 3 hours kept in ice or at 2°..8°C.

At the end of the working day discard adequately the material leftover of the STD Dilution Points.

The not used volume of Component B, STD and I.C. can be freeze at -20°C and used as described in Section E.

### N.3 Instrument programming

For programming the instrument refer to the Instrumentation Instruction Manual provided by the manufacturers.

**Important Note:** For Mx3000P set "Filter set gain settings":  
 ROX = x1, FAM = x8, VIC/JOE = x1. (see MxPro™ QPCR Software Instruction Manual, p.41)

#### N.3.1 Thermal Profile

The thermal profile is reported in the table below:

Step	Cycle	Temp.	Time
1	1	50°C	2 min
2	1	95°C	10 min
3	50	95°C	15 sec
		64°C (*)	1 min

**IMPORTANT NOTE: (\*) step for the real time data collection**

WARNING: Keep attention to program the Real-Time Thermocycler with the correct Thermal Profile following the Instrument Manual supplied by the Instrument manufacturer.

#### N.3.2 Selection of the Detectors

Following the Instruction manuals of the Real-Time thermocyclers suggested (ABI 7500, Biorad MiniOpticon and Mx3000P Stratagene) select the Detectors reported in the table here below:

Detection	Reporter	Quencher
HHV8	FAM	Non Fluorescent
Internal Control (I.C.)	JOE/VIC	Non Fluorescent
Passive Reference	ROX	Not Present

WARNING: Keep attention to program the Real-Time Thermocycler with the correct settings following the Instruments Manual supplied by the manufacturer.

### O. ASSAY SCHEME

An example of dispensation scheme for Quantitative Analysis is reported below:

#### Microplate or tubes

	1	2	3
A	STD 1 35000 copies/ µl	Sample 4	
B	STD 2 3500 copies/ µl	Sample 5	
C	STD 3 350 copies/ µl	Sample 6	
D	STD 4 35 copies/ µl	Sample 7	
E	NTC	Sample 8	
F	Sample 1	Sample 9	
G	Sample 2	Sample 10	
H	Sample 3	Sample 11	

Legenda: NTC = Negative Control STD 1,2,3,4 = HHV8 DNA Standard Curve, Sample 1,2,3,... = Samples under evaluation.

### P. INTERNAL QUALITY CONTROL

#### P.1 Pre- Analysis setting

Before starting the interpretation of the data:

- Set the "Baseline" (the background fluorescence level) as reported in the table below:

"Baseline"	
ABI™PRISM® 7500 SDS	Auto Baseline
BIORAD™ MiniOpticon®	Auto Baseline
STRATAGENE™ MX3000P®	Adaptive Baseline Important Note: <i>Do not use Mx4000 v1.00 to v3.00 algorithm</i>

- Set manually the FAM/JOE/HEX fluorescence "Threshold"

FAM fluorescence "Threshold"	
ABI™PRISM® 7500 SDS	0.1
BIORAD™ MiniOpticon®	0.03
STRATAGENE™ MX3000P®	0.1

JOE/VIC fluorescence "Threshold"	
ABI™PRISM® 7500 SDS	0.05
BIORAD™ MiniOpticon®	0.01
STRATAGENE™ MX3000P®	0.02

#### P.2 Data Analysis

A check is carried out on the STD calibrators any time the kit is used in order to verify whether their Ct values are as expected and reported in the table below.

Check FAM	Requirements
STD 1	21.5 < Ct (Threshold Cycle) < 24.5

Moreover the Slope and R2 values are checked in order to verify the quality of the run. The following requirements must be fulfilled.

Check FAM	Requirements
Slope	-3.1 < Slope < -3.9

Check FAM	Requirements
Efficiency	R <sup>2</sup> > 0.98

### Q. INTERPRETATION OF THE RESULTS AND TROUBLESHOOTING

For each samples FAM fluorescence (positive/negative Ct value) and Internal Control JOE fluorescence are assumed to validate HHV8 detection as described in the table below:

HHV8 FAM	Internal Control JOE/VIC	Assay Result
SAMPLE POSITIVE	+	CORRECT
	-	CORRECT*
SAMPLE NEGATIVE	Ct < 42	CORRECT
	Ct > 42 or undetermined	INVALID**

\*High Initial concentration of HHV8 DNA in the sample (Positive FAM Signal) can lead to REDUCED or ABSENT Fluorescent Signal of Internal Control I.C. due to the reagents Competition.

\*\* Problems may be occurred during the amplification step (inefficient or absent amplification) or during the extraction step (presence of inhibitors or initial sample containing an insufficient number of cells) leading to an incorrect result. The test procedure must be repeated starting from the Extraction step using a fresh sample coming from the patient.

For each positive samples detected by kit code HHV8DNAQT.CE a correct Quantitation of the viral load can be applied within the 3.5E+08 copies/ul and the 1.2E+00 copies/ul. HHV8 viral load must be expressed as reported in the table below:

Sample HHV8 run data (copies/μl)	HHV8 viral load (copies/μl)
Quantity > 3.5E+08	HHV8 viral load > 3.5E+08
1.2E00 ≤ Quantity ≤ 3.5E+08	<b>QUANTITATION</b>
Quantity < 1.2E+00	HHV8 viral load < 1.2E+00

**Important note:** For samples quantitation refer to Section R

The results obtained with HHV8DNAQT.CE must be interpreted by the responsible of the laboratory keeping in consideration the clinical symptoms of the patients and the other laboratory markers of Infection.

The following results are possible:

#### Troubleshooting table

	FAM	JOE/VIC	Result	CHECK
SAMPLE unknown	+	+/-	CORRECT RESULT <u>Positive</u>	<b>IMPORTANT:</b> High Initial concentration of HHV8 DNA (Positive FAM Signal) can lead to REDUCED or ABSENT Fluorescent Signal of Internal Control I.C. due to the reagents Competition.
SAMPLE unknown	-	-	ATTENTION ! POSSIBILITY OF: Inhibition, error in the procedure or malfunctioning of the Instruments	1. that the components have been prepared correctly 2. that no mistake has been done in the assay procedure; 3. That the selected detection dyes are corrected FAM for the HHV8 detection and JOE/HEX for the I.C. detection; 4. that the Analysis has been run with the correct Instrument settings; 5. that the kit has been stored correctly; 6. that no potential PCR

				inhibitors have been contaminated the tube 7. That the Extraction procedure have been executed correctly;
SAMPLE unknown	-	+	CORRECT RESULT <u>Negative</u>	
STD	+	+/-	CORRECT RESULT	<b>IMPORTANT:</b> High Initial concentration of HHV8 DNA (Positive FAM Signal) can lead to REDUCED or ABSENT Fluorescent Signal of Internal Control I.C. due to the reagents Competition.
STD	-	-	ATTENTION ! POSSIBILITY OF: Error in the pipetting or in the procedure	1. that the components have been prepared correctly 2. that no mistake has been done in the assay procedure; 3. That the selected detection dyes are corrected FAM for the HHV8 detection and JOE/HEX for the I.C. detection; 4. that the Analysis has been run with the correct Instrument settings; 5. that the kit has been stored correctly; 6. that no potential PCR inhibitors have been contaminated the tube
STD	-	+	ATTENTION ! POSSIBILITY OF: Error in the pipetting or in the procedure	1. that the components have been prepared correctly 2. that no mistake has been done in the assay procedure; 3. That the selected detection dyes are corrected FAM for the HHV8 detection and JOE/HEX for the I.C. detection; 4. that the Analysis has been run with the correct Instrument settings; 5. that the kit has been stored correctly;
NTC	-	+	CORRECT RESULT	
NTC	+	+/-	ATTENTION ! POSSIBILITY OF: Contamination	1. that the components have been prepared correctly 2. that no mistake has been done in the assay procedure; 3. That the work space and Instruments are decontaminated at regular intervals; 4.;that the kit has been stored correctly;

#### **Important notes:**

1. Interpretation of results should be done under the supervision of the responsible of the laboratory to reduce the risk of judgment errors and misinterpretations.
2. When test results are transmitted from the laboratory to an informatics centre, attention has to paid to avoid erroneous data transfer.

If the results of the test match the CORRECT ASSAY RESULT requirements stated above, proceed to the next section.

If one of more of the problems described in the table above happen, after checking, report any residual problem to the supervisor for further actions.

### R. QUANTITATION

The STD calibrators are treated as patient samples and the same volume, 10μl, is used during the amplification step. The STD calibrators concentration is expressed in copies/μl. The **Viral Genome Concentration per mL** for each patient specimen is calculated applying the following formula:

Results (copies/ml)  $\equiv \frac{\text{copies}/\mu\text{l}(\text{run data}) \times \text{Elution sample volume } (\mu\text{l})}{\text{Sample Extraction volume (ml)}}$

**Example:**

Results (copies/ml)  $\equiv \frac{1500 \times 100}{0.2}$

Results (copies/ml)  $\equiv 7.5 \text{ E}+05$

**R. PERFORMANCES**

Evaluation of Performances has been conducted in accordance to what reported in the Internal Technical Specifications or ITS. The performance evaluation was carried out in DiaPro's laboratories on materials supplied by the reference clinical labs.

**S.1 ANALYTICAL SENSITIVITY**

Analytical sensitivity may be expressed as **limit of detection** and as **limit of quantitation**.

**Limit of detection (LOD):** it is the lowest amount of target that can be detected by a test system with a stated probability.

For the NAT tests it is expressed as the smallest analyte concentration that tested in multiple repetitions gives positive results.

The **limit of detection (LOD)** is determined by testing serial dilutions containing known concentrations of the analyte.

The **LOD** is the lowest concentration of analyte that can be consistently detected (e.g. in  $\geq 95\%$  of samples under routine laboratory conditions).

In the kit code HHV8DNAQT.CE the **LOD** it was determined by analysis of 24 replicates, 8 replicates in three different runs, of the highest dilution of the analyte that can be detected in 100% of them.

The results are the following:

Detection Limit	
ABI™PRISM® 7500 SDS	0.7 copies/ $\mu\text{l}$
BIORAD™ MiniOpticon®	0.7 copies/ $\mu\text{l}$
STRATAGENE™ MX3000P®	0.7 copies/ $\mu\text{l}$

This means that there is with the Instrument listed in the above table the 100% probability that 0.7 copies/  $\mu\text{l}$  will be detected.

**S.1.1 Limit of quantitation**

The **Limit of quantitation** was determined by measuring the **linearity**, the **dynamic range** and the **reproducibility**.

The **Linearity** is the measure of the degree to which a curve approximates a straight line. It is expressed with the **SLOPE** value.

The **dynamic range** is the span of analyte concentrations for which the final output value (Ct threshold cycle) of the system is directly proportional to the analyte concentration, with acceptable trueness and precision.

The boundaries of the dynamic range are the lower and upper limits of quantitation (**Limit of quantitation**).

For the kit code HHV8DNAQT.CE a series of dilution of a DNA plasmid carrying the specific target, produced in-house, whose concentration was determined by spectrophotometer, was prepared at defined copies/ $\mu\text{l}$  in order to produce a curve of limiting dilutions. These dilutions were tested in the analytical system and their Ct (threshold cycle) determined.

The upper **limit of quantitation** is  $8.54 \log_{10}$  ( $3.5 \text{ E}+08$  copies/ $\mu\text{l}$ ) and the lower limit of quantitation is  $0.08 \log_{10}$  ( $1.2 \text{ E}+00$  copies/ $\mu\text{l}$ ).

**S.2 ANALYTICAL SPECIFICITY**

Analytical specificity is the ability of a method to detect and quantify only the target marker.

The analytical specificity of HHV8 DNA assay has been studied as follow:

1. The primer/probe Set has been choose analysing the genome target sequence with an appropriate software (LionSoft v.1.0 supplied by Biotools and Primer Express v.3.0" supplied by Applied Biosystem Inc.).
2. The primer/probe Set and the target genome sequence has been controlled by the "BLAST" software, in order to check if any of the nucleotide sequences deposited in the worldwide genomic banks has any homology with HHV8, and by the "ClustalX" software, in order to compare the genome target sequences of the different genotypes of HHV8.
3. The specificity was improved through the selection of stringent reaction conditions.
4. Samples coming from patients suffering infections due to potential interfering organisms were obtained from a reference Clinical Centre and tested.

The results are reported in the following table:

Organism	Result
CMV	negative
VZV	negative
EBV	negative
HHV6	negative
HSV1	negative
HSV2	negative

**S.3 DIAGNOSTIC SPECIFICITY AND SENSITIVITY**

**S.3.1 Diagnostic Specificity:**

Diagnostic specificity is the probability that the device gives a negative result in the absence of the target marker. So that **true negative** sample is a specimen known to be negative for the target marker and correctly classified by the device.

This parameter was studied by examining 20 HHV8 DNA negative plasma samples:

TRUE NEGATIVES	20
FALSE POSITIVES	0
TOTAL SAMPLES	20
<b>SPECIFICITY %</b>	<b>100</b>

On the basis of the results obtained **Diagnostic Specificity of the system has been calculated  $\geq 99\%$ .**

**S.3.2 Diagnostic Sensitivity**

**Diagnostic sensitivity** is the probability that the device gives a positive result in the presence of the target marker. So that **true positive** sample is a specimen known to be positive for the target marker and correctly classified by the device.

For the kit code HHV8DNAQT.CE this parameter was studied by examining 10 HHV8 DNA positive samples.

The samples have been studied in duplicates in the same run and then it has been calculated the percentage (%) of positive samples.

TRUE POSITIVES	10
FALSE NEGATIVES	0
TOTAL SAMPLES	10
<b>SENSITIVITY %</b>	<b>100</b>



On the basis of the results obtained Diagnostic Sensitivity of the system has been calculated in the 100%.

<b>Diagnostic Sensitivity</b>	100 %
<b>Diagnostic Specificity</b>	> 99.5 %

#### S.4 PRECISION

Precision shows the degree of the system's reliability. Every measurement procedure has an inherent random variation called "random error". Random error does not have a number value but it is determined by dispersion of measurement as standard deviation (DevST) and coefficient variation (CV%). Usually precision of an assay refers to the agreement between replicate measurements of the same material.

In the kit code HHV8DNAQT.CE, **precision** was expressed as intra-assay variability and inter-assay variability. 4 dilution points in 8 replicates were tested in the same run (intra-assay) and in three different runs (inter-assay).

On the basis of the results obtained Intra and inter-assay variability were then calculated.

In absence of established International parameters we have identified the following value of acceptability for the HHV8DNAQT.CE Kit:

**Intra-Assay Coefficient Variation (CV%) ≤ 10%.**

**Inter-Assay Coefficient Variation (CV%) ≤ 10%.**

#### T. LIMITATIONS

The user of this kit is advised to carefully read and understand this package insert. Strict adherence to the protocol is necessary in order to obtain reliable test results. In particular, accurate sample and reagent pipetting, application of a correct workflow along with careful programming of thermocycling step is essential for accurate and reproducible HHV8 DNA detection and quantitation.











The determination of the HHV8 DNA in a patient sample has extensive medical, social, Psychological and economic implications.

It is recommended that confidentiality, appropriate counselling and medical evaluation be considered an essential aspect of the testing sequence.

#### U. BIBLIOGRAPHY

1. Kaposi sarcoma in transplantation. Lebbé C., Legendre C., Francès C. Transplantation reviews, 2008; 22:252-261.
2. Detection of human herpesviruses HHV6, HHV7 and HHV8 in whole blood by real time PCR using the new CMV, HHV-6,7,8 R-gene kit. Deback C., Agbalika F., Scieux C., Marcelin A.G., Gautheret-Dejean A., Cherot J., Hermet L., Roger O., Agut H. J.Virol.Methods, 2008;149:285-291.
3. High level of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Oksenhendler E., Carcelain G., Aoki Y., Boulanger E., Maillard A., Clauvel J.P., and Agbalika F. Blood, 2000; 96: 2069-2073.
4. HHV8 and Kaposi's sarcoma: a time cohort study. Kennedy M.M., Lucas S.B., Jones R.R., Howells D.D., Picton S.J., Hanks E.E., McGee J. O'D., O'Leary J.J. J Clin Pathol. 1997; 50:96-100.

## 5. Symbols

LEGENDA			
	Product code		Storage temperature
	In Vitro Diagnostic Device		See use instructions
	Lot number		Manufacturer
	Expiry date		Number of tests
	CE conformity mark		Date of manufacturing



Gentaur Molecular Products  
Voortstraat 49  
1910 Kampenhout, Belgium